Lifecore Biomedical (LFCR) Reports Q1 Loss of $0.53/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Lifecore Biomedical (LFCR) PT Raised to $6 at Stephens
October 7, 2024 9:19 AM EDTStephens analyst Jacob Johnson raised the price target on Lifecore Biomedical (NASDAQ: LFCR) to $6.00 (from $5.00) while maintaining a Equal Weight rating.
The analyst comments "LFCR posted 1Q25 revenue/gross margins that came in ahead of us and consensus estimates. Elevated OpEx... More
Stephens Reiterates Equal Weight Rating on Lifecore Biomedical (LFCR)
October 4, 2024 1:16 PM EDTStephens analyst Jacob Johnson reiterated an Equal Weight rating and $5.00 price target on Lifecore Biomedical (NASDAQ: LFCR).
The analyst comments "LFCR reported a 1Q25 revenue beat vs. us/consensus which flowed through to better than expected gross margins, while adj. EBITDA came in below... More
